NVS vs PGEN
NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience. PGEN: A commercial-stage precision medicine company leveraging proprietary adenoviral and CAR-T platforms to address intractable diseases, notably including the FDA-approved RRP therapy Papzimeos.
Side-by-side fundamentals
| Metric | NVS | PGEN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $143.11 | $7.60 | |
| Market cap | $227.4B | $2.7B | |
| P/E as of 2026-09-03 | 21.95 | n/a | |
| Net margin FY2025, SEC XBRL | n/a | -2588.2% | |
| Operating margin FY2025, SEC XBRL | n/a | -1141.1% | |
| ROE FY2025, SEC XBRL | +30.0% | -1198.6% | NVS higher |
| ROA FY2025, SEC XBRL | +12.6% | -161.2% | NVS higher |
| Debt / equity as of 2026-09-03 | 1.18 | 2.15 | NVS lower |
| Revenue growth (YoY) as of 2026-09-03 | +3.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | n/a | -28.9% | |
| Dividend yield as of 2026-09-03 | +3.4% | n/a | |
| Beta as of 2026-09-03 | 0.23 | 1.56 | |
| 1-year return as of 2026-10-08 close | +8.2% | +136.0% | PGEN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.